AnaptysBio, Inc.
ANAB
Rank in Stocks
#7173
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering... AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The companyโs products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Share Price
$47.97
Last synced: 2026-11-09
Market Cap
$1.43B
Change (1 day)
3.27%
Change (1 year)
114.44%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade AnaptysBio, Inc. (ANAB)
Category
Healthcare
Operating Margin for AnaptysBio, Inc. (ANAB)
Operating Margin as of November 2026 TTM: 56.36%
According to AnaptysBio, Inc.'s latest financial reports, its current operating margin (TTM) is 56.36%. At the end of 2025 the company had an operating margin of 20.42%.
Operating Margin history for AnaptysBio, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 56.36% | 176.00% |
| 2025 | 20.42% | -116.22% |
| 2024 | -125.93% | -86.86% |
| 2023 | -958.27% | -14.40% |
| 2022 | -1,119.41% | 1,144.76% |
| 2021 | -89.93% | 182.44% |
| 2020 | -31.84% | -97.63% |
| 2019 | -1,342.90% | 0.63% |
| 2018 | -1,334.44% | 363.65% |
| 2017 | -287.81% | 1,487.48% |
| 2016 | -18.13% | -4.12% |
| 2015 | -18.91% | -161.50% |
| 2014 | 30.75% | -131.89% |
| 2013 | -96.43% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.32% |
US
|
|
| -149.01% | -102.64% |
US
|
|
| 25.57% | -99.55% |
AU
|
|
| 31.23% | -99.45% |
BE
|
|
| 29.35% | -99.48% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about AnaptysBio, Inc.'s operating margin
What is AnaptysBio, Inc.'s operating margin?
AnaptysBio, Inc.'s operating margin is 56.36%, as of Nov 2026.
What was AnaptysBio, Inc.'s operating margin in 2025?
In 2025, AnaptysBio, Inc.'s operating margin was 20.42%, compared with -125.93% in 2024.
How has AnaptysBio, Inc.'s operating margin changed since 2020?
From 2020 to 2025, AnaptysBio, Inc.'s operating margin was highest in 2025 (20.42%) and lowest in 2022 (-1,119.41%).
How does AnaptysBio, Inc.'s operating margin compare with similar companies?
AnaptysBio, Inc.'s operating margin (56.36%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.